Atara enlists Juno co-founder Michel Sadelain in CAR-T effort; Valeant no more, Bausch is the new marquee name
→ The day after Atara announced that it is bringing Genentech vet Dietmar Berger on board as R&D chief, the biotech is back with a signed deal aimed at expanding its work with Memorial Sloan Kettering on off-the-shelf CAR-Ts. As part of that arrangement, Atara is getting an exclusive relationship with Michel Sadelain, the top CAR-T investigator who helped create the scientific foundation for Juno. Said Sadelain: “We are eager to work with Atara to continue advancing promising allogeneic T-cell immunotherapy technologies that originated at MSK. The new CAR T technologies seek to overcome persistent therapeutic challenges, such as safety and tolerability, durability of treatment response, and activity in areas of significant unmet medical need that are underserved by the current generation of CAR T immunotherapies.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.